Table 3.

Phenotype–pathway map genes and their stage of clinical drug development within prostate cancer (source: http://ClinicalTrials.gov and PubMed data as of December 2010)

Prioritized gene	Relation to prostate cancer	Signature or cancer gene	Clinical drug development
CCND3	Established47	Both	No data
CDK(4/6/7)	Well-established48	Cancer/cancer/signature	Yes
CDKN1C	Well-established49	Signature	Tumor suppressor
CDKN(2A/2B/2C)	Established50	Cancer/signature/signature	Tumor suppressor
E2F1	Well-established51	Signature	No data
FGF(1/2), FGFR(1/3)	Well-established42	Signature/signature/both/cancer	Yes
HDAC1	Well-established52	Signature	Yes
IFNGR1	Established53	Signature	No data
ITGAV	Established54	Signature	No data
JAK2	Well-established55	Both	Yes
NFKB1	Well-established56	Signature	Yes
PCNA	Well-established40	Signature	No data
PDGF(A/B), PDGFR(A/B)	Well-established13	Signature/both/both/both	Yes
PI3KR1/PI3KCA	Well-established38	Both/cancer	Yes
RB1	Well-established57	Cancer	Tumor suppressor
RUNX1	Established58	Both	No data
STAT1	Role unclear46	Signature	No data
SUZ12	No data	Cancer	Yes

PCNA, proliferating cell nuclear antigen.